MentalHealthDaily

Parkinson’s Disease Prevention: Prodromal Symptoms, RBD, Early Intervention Trials

by GLOOM

Photoreal illustration of a brain with prodromal pathology and a clock indicating early-window intervention opportunity for Parkinson's prevention.

Parkinson’s disease has a years-to-decades prodromal stage where motor symptoms haven’t yet emerged but pathology is accumulating. A 2026 review by Schaeffer et al. synthesizes the case for (and limits of) intervening during this window — with implications for high-risk individuals weighing whether to enter preventive trials.1 Research Highlights Prodromal Parkinson’s disease is the period …

GLP-1 Drugs for Parkinson’s: Lixisenatide Signal, Exenatide Miss

by GLOOM

Stylized illustration representing GLP-1 receptor agonists being investigated as potential disease-modifying treatments for Parkinson's disease.

Parkinson’s disease is the second most common neurodegenerative disorder, affecting around 10 million people worldwide. The mental-health burden is heavy: depression affects 40-50% of patients9, anxiety 30-40%, sleep disorders most patients eventually, and dementia about a third of long-duration cases. Standard treatment with levodopa controls motor symptoms but doesn’t slow the underlying neurodegeneration. The clinical …